PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1538655
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1538655
Global Cell and Gene Therapy Market Size Study, by Therapy Type, by Application and Regional Forecasts 2022-2032
The Global Cell and Gene Therapy Market was valued at approximately USD 12.62 billion in 2023 and exhibiting a compound annual growth rate (CAGR) of 18.04% during the forecast period 2024-2032. Cell and gene therapy are advanced medical treatments designed to address and potentially cure genetic disorders and diseases at a cellular or genetic level. Cell therapy involves the infusion or transplantation of living cells to repair or replace damaged tissues and organs, such as using stem cells to regenerate cells in diseases such as leukemia. Gene therapy, on the other hand, aims to correct or modify faulty genes responsible for disease by inserting, altering, or removing genetic material within a patient's cells. The surge in the incidence of cancer and rare disorders, along with an increase in approvals for gene and cell therapy products, is significantly propelling the market growth. Additionally, rising investments in the cell and gene therapy sector are expected to provide ample growth opportunities in the future.
The growing incidences of cancer and rare disorders are significantly driving demand for the cell and gene therapy market. As the global prevalence of these conditions rises, traditional treatment methods often fall short, creating an urgent need for innovative solutions. Cell and gene therapies offer targeted and potentially curative approaches by addressing the underlying genetic and cellular causes of these diseases. For cancers, therapies can target specific cancer cells, while for rare disorders, gene editing or replacement can correct genetic defects. This increasing need for effective treatments spurs investment and research in advanced therapies, driving market growth. The promise of personalized and precision medicine to improve patient outcomes further fuels the expansion of the cell and gene therapy sector.
The key region in the Global Cell and Gene Therapy Market includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2023, North America dominates the market in terms of revenue, driven by the prevalence of chronic diseases, availability of reimbursements, and significant healthcare expenditure on gene therapy drugs. The US dominated the North American market, holding a substantial share. Asia-Pacific is projected to grow at the highest CAGR, attributed to a large population base, heightened healthcare awareness, and increasing cancer cases. The region's growth is further supported by pharmaceutical market expansion, government initiatives, and a surge in research and development activities.
Major market players included in this report are:
- Novartis AG
- Bristol-Myers Squibb Company
- Amgen Inc.
- Aurion Biotech
- Sarepta Therapeutics, Inc.
- Ferring B.V.
- Sibiono Genetech Co, Ltd., Shenzhen
- Bluebird Bio, Inc.
- Kite Pharmaceuticals, Inc.
- Janssen Global Services
The detailed segments and sub-segment of the market are explained below:
By Therapy Type
- Cell Therapy
- Gene Therapy
By Application
- Cancer
- Neurological Disorders
- Cardiovascular Disorders
- Rare Diseases
- Ophthalmology
- Blood Disorders
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Cell and Gene Therapy Market Executive Summary
- 1.1. Global Cell and Gene Therapy Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Therapy Type
- 1.3.2. By Application
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Cell and Gene Therapy Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Cell and Gene Therapy Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Growing Incidences of Cancer and Rare Disorders
- 3.1.2. Increasing Approval for Gene and Cell Therapy Products
- 3.1.3. Growing Investments in the Field of Cell and Gene Therapy
- 3.2. Market Challenges
- 3.2.1. High Cost of Treatment
- 3.2.2. Complexity of Regulatory Approvals
- 3.3. Market Opportunities
- 3.3.1. Technological Advancements
- 3.3.2. Expansion in Emerging Markets
Chapter 4. Global Cell and Gene Therapy Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Cell and Gene Therapy Market Size & Forecasts by Therapy Type 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Cell and Gene Therapy Market: Therapy Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Cell Therapy
- 5.2.2. Gene Therapy
- 5.2.2.1. Autologous
- 5.2.2.2. Allogenic
- 5.2.2.3. Ex-vivo
- 5.2.2.4. In-vivo
Chapter 6. Global Cell and Gene Therapy Market Size & Forecasts by Application 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Cell and Gene Therapy Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Cancer
- 6.2.2. Neurological Disorders
- 6.2.3. Cardiovascular Disorders
- 6.2.4. Rare Diseases
- 6.2.5. Ophthalmology
- 6.2.6. Blood Disorders
- 6.2.7. Others
Chapter 7. Global Cell and Gene Therapy Market Size & Forecasts by Region 2022-2032
- 7.1. North America Cell and Gene Therapy Market
- 7.1.1. U.S. Cell and Gene Therapy Market
- 7.1.1.1. Therapy Type breakdown size & forecasts, 2022-2032
- 7.1.1.2. Application breakdown size & forecasts, 2022-2032
- 7.1.2. Canada Cell and Gene Therapy Market
- 7.1.1. U.S. Cell and Gene Therapy Market
- 7.2. Europe Cell and Gene Therapy Market
- 7.2.1. UK Cell and Gene Therapy Market
- 7.2.2. Germany Cell and Gene Therapy Market
- 7.2.3. France Cell and Gene Therapy Market
- 7.2.4. Spain Cell and Gene Therapy Market
- 7.2.5. Italy Cell and Gene Therapy Market
- 7.2.6. Rest of Europe Cell and Gene Therapy Market
- 7.3. Asia-Pacific Cell and Gene Therapy Market
- 7.3.1. China Cell and Gene Therapy Market
- 7.3.2. India Cell and Gene Therapy Market
- 7.3.3. Japan Cell and Gene Therapy Market
- 7.3.4. Australia Cell and Gene Therapy Market
- 7.3.5. South Korea Cell and Gene Therapy Market
- 7.3.6. Rest of Asia Pacific Cell and Gene Therapy Market
- 7.4. Latin America Cell and Gene Therapy Market
- 7.4.1. Brazil Cell and Gene Therapy Market
- 7.4.2. Mexico Cell and Gene Therapy Market
- 7.4.3. Rest of Latin America Cell and Gene Therapy Market
- 7.5. Middle East & Africa Cell and Gene Therapy Market
- 7.5.1. Saudi Arabia Cell and Gene Therapy Market
- 7.5.2. South Africa Cell and Gene Therapy Market
- 7.5.3. Rest of Middle East & Africa Cell and Gene Therapy Market
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. Novartis AG
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Market Strategies
- 8.3.2. Bristol-Myers Squibb Company
- 8.3.3. Amgen Inc.
- 8.3.4. Aurion Biotech
- 8.3.5. Sarepta Therapeutics, Inc.
- 8.3.6. Ferring B.V.
- 8.3.7. Sibiono Genetech Co, Ltd., Shenzhen
- 8.3.8. Bluebird Bio, Inc.
- 8.3.9. Kite Pharmaceuticals, Inc.
- 8.3.10. Janssen Global Services
- 8.3.1. Novartis AG
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
